Physician profile
Adam D Sauls
NPI 1568297463
$1,646.88
in general payments reported to CMS, 2019-2025
10 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $544 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $897.46 | 2024-2025 | Infuse, Vyzulta, Miebo |
| Tarsus Pharmaceuticals, INC. | $179.85 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $150.14 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $125.48 | 2025 | Acuvue |
| Alcon Vision LLC | $112.59 | 2025 | Hydrus Microstent |
| Harrow Eye, LLC | $73.46 | 2024-2025 | Vevye |
| Abbvie INC. | $31.55 | 2025 | |
| Ani Pharmaceuticals, INC. | $28.00 | 2025 | Purified Cortrophin Gel |
| Alimera Sciences, INC. | $24.65 | 2024 | Yutiq, Iluvien |
| Oyster Point Pharma, INC. | $23.70 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Sauls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.